Faeth Therapeutics, Inc. FTH
Faeth Therapeutics, Inc. (Nasdaq: FTH) is an oncology drug developer. Its lead program, PIKTOR (serabelisib + sapanisertib), is in Phase 2 for second-line advanced endometrial cancer; HR+/HER2- advanced breast cancer. Its next catalyst on record is PIKTOR (FTH-PIK-201): Phase 2 topline data in advanced endometrial cancer (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PIKTOR (FTH-PIK-201) — Phase 2 topline data in advanced endometrial cancer (2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PIKTOR (FTH-PIK-201) | second-line advanced endometrial cancer | small molecule | Phase 2 |
| PIKTOR (FTH-PIK-101) | HR+/HER2- advanced breast cancer | small molecule | Phase 2 |
| solnerstotug (SNS-101) | solid tumors (VISTA) | antibody | Phase 2 |
| NEAAR program | — | unclear | Pre-clinical |
| IEM program | — | unclear | Pre-clinical |
Recent results and decisions
- May 15, 2026started First patient dosed in April 2026 in Phase 1b/2 PIKTOR trial in HR+/HER2- advanced breast cancer; interim data expected 2027.
In April 2026, the first patient was dosed in the Phase 1b/2 trial evaluating PIKTOR for the treatment of HR+/HER2- advanced breast cancer (Study FTH-PIK-101). Interim data from the trial is expected in 2027.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.